Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion

被引：0
|
作者：
Morikawa, K. [1 ]
Kakinuma, K. [1 ]
Inoue, T. [1 ]
Mineshita, M. [1 ]
机构：
[1] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFR-mutant NSCLC; Exon; 20; insertion;
D O I：
10.1016/j.jtho.2019.08.1032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.09-03
引用
收藏
页码：S496 / S496
页数：1
相关论文
共 50 条
  • [21] Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
    Zhang, Shannon S.
    Zhu, Viola W.
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 61 - 65
  • [22] Preliminary clinical investigations and mechanism exploration of furmonertinib in NSCLC with EGFR exon 20 insertion
    Zhang, X.
    Feng, G.
    Han, H.
    Dong, B.
    Yang, Y.
    Zhu, H.
    Fan, S.
    Tang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S63 - S63
  • [23] Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC
    Dorkhom, N. V.
    Cannon, M.
    Cohen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S645 - S645
  • [24] The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
    Zwierenga, F.
    Zhang, L.
    Melcr, J.
    Schuuring, E.
    van Veggel, B. A. M. H.
    de Langen, A. J.
    Groen, H. J. M.
    Groves, M. R.
    van der Wekken, A. J.
    LUNG CANCER, 2024, 197
  • [25] Molecular characteristics of EGFR exon20 mutations in NSCLC patients.
    Ji, Yinghua
    Wang, Jin
    Meng, Xiangli
    Xie, Jinling
    Lu, Ping
    Li, Mengmeng
    Luo, Ningning
    Qi, Yingxue
    Zhu, Xiaofeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
    Oxnard, Geoffrey R.
    Lo, Peter C.
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Lindeman, Neal I.
    Butaney, Mohit
    Jackman, David M.
    Johnson, Bruce E.
    Jaenne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (02) : 179 - 184
  • [27] Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation
    Urban, Laszlo
    Doczi, Robert
    Vodicska, Barbara
    Tihanyi, Dora
    Horvath, Magdolna
    Kormos, Dora
    Takacs, Istvan
    Papai-Szekely, Zsolt
    Poka-Farkas, Zsuzsanna
    Varkondi, Edit
    Schwab, Richard
    Hegedus, Csilla
    Valyi-Nagy, Istvan
    Petak, Istvan
    CLINICAL LUNG CANCER, 2021, 22 (01) : E112 - E115
  • [28] Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
    Ou, Sai-Hong Ignatius
    Lin, Huamao M.
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Nguyen, Danny
    Neal, Joel W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10):
  • [29] Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
    Yang, J. C. -H.
    Wang, M.
    Mitchell, P.
    Fang, J.
    Nian, W.
    Chiu, C-H.
    Zhou, J.
    Zhao, Y.
    Su, W. -C.
    Camidge, R.
    Yang, T. -Y.
    Zhu, V.
    Millward, M.
    Fan, Y.
    Huang, W. -T.
    Cheng, Y.
    Jiang, L.
    Brungs, D.
    Bazhenova, L. B.
    Lee, C. K.
    Gao, B.
    Zheng, L.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S410 - S411
  • [30] Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
    van Veggel, Bianca
    de Langen, Adrianus J.
    Hashemi, Sayed M. S.
    Monkhorst, Kim
    Heideman, Danielle A. M.
    Thunnissen, Erik
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1222 - 1226
12345